tiprankstipranks
Trending News
More News >
Biovica International AB Class B (SE:BIOVIC.B)
:BIOVIC.B

Biovica International AB Class B (BIOVIC.B) Price & Analysis

Compare
0 Followers

BIOVIC.B Stock Chart & Stats


Financials

BIOVIC.B FAQ

What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was kr0.50 and its highest was kr3.19 in the past 12 months.
    What is Biovica International AB Class B’s market cap?
    Biovica International AB Class B’s market cap is kr72.82M.
      When is Biovica International AB Class B’s upcoming earnings report date?
      Biovica International AB Class B’s upcoming earnings report date is Sep 11, 2025 which is in 62 days.
        How were Biovica International AB Class B’s earnings last quarter?
        Biovica International AB Class B released its earnings results on Jun 18, 2025. The company reported -kr0.21 earnings per share for the quarter, beating the consensus estimate of -kr0.31 by kr0.1.
          Is Biovica International AB Class B overvalued?
          According to Wall Street analysts Biovica International AB Class B’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Biovica International AB Class B pay dividends?
            Biovica International AB Class B does not currently pay dividends.
            What is Biovica International AB Class B’s EPS estimate?
            Biovica International AB Class B’s EPS estimate is -0.11.
              How many shares outstanding does Biovica International AB Class B have?
              Biovica International AB Class B has 84,073,710 shares outstanding.
                What happened to Biovica International AB Class B’s price movement after its last earnings report?
                Biovica International AB Class B reported an EPS of -kr0.21 in its last earnings report, beating expectations of -kr0.31. Following the earnings report the stock price went down -8.732%.
                  Which hedge fund is a major shareholder of Biovica International AB Class B?
                  Currently, no hedge funds are holding shares in SE:BIOVIC.B

                  Company Description

                  Biovica International AB Class B

                  Biovica International AB Class B (BIOVIC.B) is a Swedish biotechnology company that specializes in the development and commercialization of innovative diagnostic tests for cancer treatment. The company's flagship product, DiviTum, is a non-invasive blood test used to measure cell proliferation rates, aiding healthcare professionals in monitoring and optimizing cancer therapies. Operating in the healthcare and biotechnology sectors, Biovica focuses on providing solutions that improve patient outcomes and support personalized medicine initiatives.

                  BIOVIC.B Stock 12 Month Forecast

                  Average Price Target

                  kr1.00
                  ▲(41.28%Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","1":"kr1","2":"kr2","3":"kr3","-1":"-kr1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.0031208201,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.0031208201,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.0031208201,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.7233169861615384,0.7466339723230768,0.7699509584846154,0.7932679446461538,0.8165849308076922,0.8399019169692307,0.8632189031307691,0.8865358892923076,0.9098528754538461,0.9331698616153845,0.956486847776923,0.9798038339384614,{"y":1.0031208201,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.7233169861615384,0.7466339723230768,0.7699509584846154,0.7932679446461538,0.8165849308076922,0.8399019169692307,0.8632189031307691,0.8865358892923076,0.9098528754538461,0.9331698616153845,0.956486847776923,0.9798038339384614,{"y":1.0031208201,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.7233169861615384,0.7466339723230768,0.7699509584846154,0.7932679446461538,0.8165849308076922,0.8399019169692307,0.8632189031307691,0.8865358892923076,0.9098528754538461,0.9331698616153845,0.956486847776923,0.9798038339384614,{"y":1.0031208201,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.63,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.96,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.615,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.185,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.52,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.175,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.012,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.7,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.7,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Active Biotech AB
                  Biosergen AB
                  Spago Nanomedical AB
                  Nanologica AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis